Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 3/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | SCN1A | P35498 | 1/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1036797 | 0.81 | SLC2A1 (0.42) | SLC2A1KCNH2MTNR1AMTNR1BMCHR1 | |
| SCHEMBL2822641 | 0.78 | KCNH2 (0.49) | SLC2A1KCNH2 | |
| SCHEMBL3155389 | 0.75 | MTNR1A (0.48) | SLC2A1KCNH2MTNR1AMTNR1BPRMT5 | |
| SCHEMBL3153644 | 0.74 | MTNR1A (0.41) | SLC2A1KCNH2MTNR1AMTNR1B | |
| SCHEMBL3541372 | 0.73 | KCNH2 (0.52) | SLC2A1KCNH2 | |
| SCHEMBL3328929 | 0.72 | CHRM1 (0.42) | SLC2A1MTNR1AMTNR1BPRMT5WDR77 | |
| SCHEMBL3333076 | 0.72 | CHRM1 (0.42) | SLC2A1MTNR1AMTNR1BPRMT5WDR77 | |
| SCHEMBL2937076 | 0.71 | KCNH2 (0.45) | SLC2A1KCNH2 | |
| SCHEMBL1267791 | 0.71 | SLC2A1 (0.40) | SLC2A1KCNH2MTNR1AMTNR1B | |
| SCHEMBL3148938 | 0.71 | SLC2A1 (0.41) | SLC2A1KCNH2MTNR1AMTNR1BMCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2041145-B1 | AZATRICYCLIC COMPOUNDS AND THEIR USE | GLAXO GROUP LTD (GB) | 2010-10-27 | — | — | EP | disclosed |
| US-20100004230-A1 | AZATRICYCLIC COMPOUNDS AND THEIR USE | GLAXO GROUP LIMITED (GB) | 2010-01-07 | — | — | US | disclosed |
| EP-2041145-A1 | AZATRICYCLIC COMPOUNDS AND THEIR USE | Glaxo Group Limited (GB) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008003690-A1 | AZATRICYCLIC COMPOUNDS AND THEIR USE | GLAXO GROUP LIMITED (GB) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004230-A1 | AZATRICYCLIC COMPOUNDS AND THEIR USE | AADAC, AZI2, NNMT | SLC2A1 4507/4885KCNH2 2592/4885MTNR1A 2202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.